Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Multiple sclerosis

Oral BG12 for treatment of relapsing–remitting MS

Nature Reviews Neurology volume 9, pages 8–10 (2013)Cite this article

Subjects

Several oral drugs have been developed in recent years for treatment of relapsing–remitting multiple sclerosis. Two large phase III trials have now clearly demonstrated the clinical efficacy and good safety profile of oral dimethyl fumarate (BG12)—an anti-inflammatory and cytoprotective agent—in patients with this disease.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Compston, A. & Coles, A. Multiple sclerosis. Lancet 372, 1502–1517 (2008).

    Article  CAS  Google Scholar 

  2. Schweckendiek, W. Treatment of psoriasis vulgaris [German]. Med. Monatsschr. 13, 103–104 (1959).

    CAS  PubMed  Google Scholar 

  3. Schimrigk, S. et al. Oral fumaric acid esters for the treatment of active multiple sclerosis: an open-label, baseline-controlled pilot study. Eur. J. Neurol. 13, 604–610 (2006).

    Article  CAS  Google Scholar 

  4. Kappos, L. et al. Efficacy and safety of oral fumarate in patients with relapsing–remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet 372, 1463–1472 (2008).

    Article  CAS  Google Scholar 

  5. Gold, R. et al. Placebo-controlled phase 3 study of oral BG12 for relapsing multiple sclerosis. N. Engl. J. Med. 376, 1098–1107 (2012).

    Article  Google Scholar 

  6. Fox, R. J. et al. Placebo-controlled phase 3 study of oral BG12 or glatiramer in multiple sclerosis. N. Engl. J. Med. 376, 1087–1097 (2012).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurology, Cologne City Hospitals, University of Cologne, Ostmerheimerstrasse 200, 51109, Cologne, Germany

    Volker Limmroth

Authors
  1. Volker Limmroth
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

The author declares no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Limmroth, V. Oral BG12 for treatment of relapsing–remitting MS. Nat Rev Neurol 9, 8–10 (2013). https://doi.org/10.1038/nrneurol.2012.231

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrneurol.2012.231

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing